A recent study indicates that people who stop using new GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass far faster than those who end conventional lifestyle plans.
Published data in a leading medical journal points out that while overweight individuals frequently drop about a fifth of their body weight while on the medication, the weight comes back at an estimated rate of nearly a kilo each month after stopping.
"Users using such treatments need to be informed of the potential of fast rebound weight gain when the medication is stopped," cautioned expert Dr. Susan Jebb.
Such speed of regain means a reversion to pre-treatment mass in about 18 months.
Analyzing Approaches
The analysis, which looked at 37 of trials involving over 9,000 of patients, compared the outcomes of the injectable medications with conventional dieting.
The team emphasize that individuals who shed pounds through diet and exercise generally experience a slower weight regain—approximately 0.1 kg a month—once they finish.
The Reason for the Rapid Rebound
Doctors believe the mode of action of the jabs accounts for the accelerated weight return.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Sustained high doses of the hormone concentrations several times higher than normal might result in the body to produce less of its own natural hormone, and may also diminish sensitivity to its effects," said Dr. Adam Collins, a dietetics expert.
"Discontinuation of this GLP-1 'fix' means appetite is no longer kept in check, making excessive eating a significant risk."
A Chronic Condition?
The NHS recommend the injections for individuals with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Many experts argue that, due to the significant potential of relapse, the therapy is often life-long.
This opinion is echoed by drug manufacturers, who state that the findings "underscore the long-term character of excess weight," comparing it to managing diseases like diabetes.
User Accounts
Individuals who have stopped the jabs describe a sudden return of appetite.
"It was like a trigger that goes on and I was suddenly ravenous," described an individual.
The struggle is exacerbated if individuals have not adopted lasting dietary or behavioural changes during treatment.
Significant Use
Figures indicate that a significant number of people in the UK have tried these injections in the last 12 months, with interest continuing to grow.
- Use is higher among women compared to men.
- The middle-aged age group shows the greatest usage rates.
- A large proportion access the medications through private healthcare rather than the NHS.
In conclusion, clinicians emphasize that while GLP-1 drugs are powerful tools for weight loss, they are not a standalone cure and long-term success hinges on ongoing lifestyle management.
